The effect of tamsulosin in ureteroscopic surgery in dilation of ureter and improve stent-related symptom

The effect of tamsulosin in ureteroscopic surgery in dilation of ureter and improve stent-related symptom: A prospective, randomized study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0004394

Enrollment

200

Registered

2019-10-29

Start date

2019-11-20

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : After dividing the group into four groups according to the randomized preoperative procedure, test group 1 continued to take tamsulosin 0.4mg HS up to the day before surgery and continued until

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients between 20 and 80 years old who are planning to undergo ureteroscopy due to unilateral kidney and ureter stones. 2. The size of stones is for patients whose total size of all stones in a single kidney or ureter is greater than 5mm and less than 7cm. 3. Patients who voluntarily decided to participate in this clinical study and signed a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of hypersensitivity to tamsulosin or its components 2. Patients diagnosed with orthostatic hypotension 3. Patients with severe liver disorder 4. Patients with Galactose intolerance, Lapp lactose deficiency, Glucose-galactose malabsorption 5. Patients with severe renal impairment (KDIGO CKD grade 3 or higher) 6. Patients with history of renal ureter cancer and bladder cancer 7. Patients with a history of ureteral stenosis 8. Patients with febrile urinary tract infection (if there is evidence of fever and urinary tract infection above 38 degrees) 9. Patients who are single kidneys 10. Patients with a history of using tamsulosin, calcium channel blockers and steroids within the last 4 weeks 11. Patients with a history of previous intrapelvic surgery or radiation 12. Women who may be pregnant or pregnant 13. Nursing mothers 14. If there is an active disease judged by the researcher to be unsuitable for participation in the study 15. Patients with a history of previous unilateral renal and ureteral stones or extracorporeal shock wave lithotripsy 16. Patient with ureteral stent inserted before surgery 17. Patients taking Warfarin and H2 receptor blocker 18. Patients taking CYP3A4 or CYP2D6 inhibitors

Design outcomes

Primary

Measure	Time frame
The difference in USSQ scores between groups.	—

Secondary

Measure	Time frame
The size of the ureteral access sheath inserted during surgery.	—

Countries

Korea, Republic of

Contacts

Public ContactHankyu Chae

Asan Medical Center

hanqsinopoli@gmail.com+82-2-3010-0147

Outcome results